Discovery of compounds that protect tyrosine hydroxylase activity through different mechanisms.

[1]  J. Haavik,et al.  Functional Studies of Tyrosine Hydroxylase Missense Variants Reveal Distinct Patterns of Molecular Defects in Dopa-Responsive Dystonia , 2014, Human mutation.

[2]  G. Briggs,et al.  Catalytic domain surface residues mediating catecholamine inhibition in tyrosine hydroxylase. , 2014, Journal of biochemistry.

[3]  B. Cormand,et al.  Levodopa‐induced dyskinesias in tyrosine hydroxylase deficiency , 2013, Movement disorders : official journal of the Movement Disorder Society.

[4]  A. C. Kroksveen,et al.  Quantitative proteomics comparison of arachnoid cyst fluid and cerebrospinal fluid collected perioperatively from arachnoid cyst patients , 2013, Fluids and Barriers of the CNS.

[5]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[6]  Aurora Martínez,et al.  Send Orders of Reprints at Reprints@benthamscience.net Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones † , 2022 .

[7]  J. Sancho,et al.  Structural and Mechanistic Basis of the Interaction between a Pharmacological Chaperone and Human Phenylalanine Hydroxylase , 2012, Chembiochem : a European journal of chemical biology.

[8]  N. Greig,et al.  Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. , 2012, CNS & neurological disorders drug targets.

[9]  S. Gersting,et al.  Novel pharmacological chaperones that correct phenylketonuria in mice. , 2012, Human molecular genetics.

[10]  P. Conn,et al.  Therapeutic Rescue of Misfolded Mutants: Validation of Primary High Throughput Screens for Identification of Pharmacoperone Drugs , 2011, PloS one.

[11]  R. Hennekam.  Care for patients with ultra-rare disorders. , 2011, European journal of medical genetics.

[12]  S. Daubner,et al.  Tyrosine hydroxylase and regulation of dopamine synthesis. , 2011, Archives of biochemistry and biophysics.

[13]  A. Gronenborn,et al.  The Regulatory Subunit of PKA-I Remains Partially Structured and Undergoes β-Aggregation upon Thermal Denaturation , 2011, PloS one.

[14]  V. Wong,et al.  Expanding Phenotype and Clinical Analysis of Tyrosine Hydroxylase Deficiency , 2011, Journal of child neurology.

[15]  J. Haavik,et al.  Effect of pharmacological chaperones on brain tyrosine hydroxylase and tryptophan hydroxylase 2 , 2010, Journal of neurochemistry.

[16]  D. Zafeiriou,et al.  Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. , 2010, Brain : a journal of neurology.

[17]  Anna M. Lieb,et al.  The biological significance of substrate inhibition: A mechanism with diverse functions , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.

[18]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[19]  Christopher R. Corbeil,et al.  Modeling Reality for Optimal Docking of Small Molecules to Biological Targets , 2009 .

[20]  L. Dangott,et al.  Identification by hydrogen/deuterium exchange of structural changes in tyrosine hydroxylase associated with regulation. , 2009, Biochemistry.

[21]  Lina Baranauskienė,et al.  Measurement of Nanomolar Dissociation Constants by Titration Calorimetry and Thermal Shift Assay – Radicicol Binding to Hsp90 and Ethoxzolamide Binding to CAII , 2009, International journal of molecular sciences.

[22]  P. Conn,et al.  Drug development and the cellular quality control system. , 2009, Trends in pharmacological sciences.

[23]  D. Zafeiriou,et al.  Tyrosine hydroxylase deficiency with severe clinical course. , 2009, Molecular genetics and metabolism.

[24]  A. Velázquez‐Campoy,et al.  Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. , 2008, The Journal of clinical investigation.

[25]  J. Haavik,et al.  Tetrahydrobiopterin shows chaperone activity for tyrosine hydroxylase , 2008, Journal of neurochemistry.

[26]  J. Haavik,et al.  Mutations in human monoamine‐related neurotransmitter pathway genes , 2008, Human mutation.

[27]  J. Haavik,et al.  Endogenous tetrahydroisoquinolines associated with Parkinson’s disease mimic the feedback inhibition of tyrosine hydroxylase by catecholamines , 2008, The FEBS journal.

[28]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[29]  D. Clarke,et al.  Chemical and pharmacological chaperones as new therapeutic agents , 2007, Expert Reviews in Molecular Medicine.

[30]  M. Mann,et al.  In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.

[31]  N. Hayashi,et al.  Molecular mechanism for pterin-mediated inactivation of tyrosine hydroxylase: formation of insoluble aggregates of tyrosine hydroxylase. , 2006, Journal of biochemistry.

[32]  Daumantas Matulis,et al.  Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. , 2005, Biochemistry.

[33]  J. Haavik,et al.  Different properties of the central and peripheral forms of human tryptophan hydroxylase , 2005, Journal of neurochemistry.

[34]  R. Stevens,et al.  Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Daubner,et al.  Effects of mutations in tyrosine hydroxylase associated with progressive dystonia on the activity and stability of the protein , 2004, Proteins.

[36]  S. Brothers,et al.  Pharmacologic Rescue of Conformationally‐Defective Proteins: Implications for the Treatment of Human Disease , 2004, Traffic.

[37]  Michel Bouvier,et al.  Pharmacological chaperones: potential treatment for conformational diseases , 2004, Trends in Endocrinology & Metabolism.

[38]  J. Haycock.  Species differences in the expression of multiple tyrosine hydroxylase protein isoforms , 2002, Journal of neurochemistry.

[39]  Victor S. Lobanov,et al.  High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery , 2001 .

[40]  K. Kobayashi.  Role of catecholamine signaling in brain and nervous system functions: new insights from mouse molecular genetic study. , 2001, The journal of investigative dermatology. Symposium proceedings.

[41]  T. Flatmark,et al.  The Effect of Substrate, Dihydrobiopterin, and Dopamine on the EPR Spectroscopic Properties and the Midpoint Potential of the Catalytic Iron in Recombinant Human Phenylalanine Hydroxylase* , 2001, The Journal of Biological Chemistry.

[42]  P. Fitzpatrick,et al.  Limited proteolysis of tyrosine hydroxylase identifies residues 33-50 as conformationally sensitive to phosphorylation state and dopamine binding. , 1999, Archives of biochemistry and biophysics.

[43]  K. Mori,et al.  Dopamine Inhibition of Human Tyrosine Hydroxylase Type 1 Is Controlled by the Specific Portion in the N‐Terminus of the Enzyme , 1999, Journal of neurochemistry.

[44]  T. Nabeshima,et al.  Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission , 1998, Journal of neuroscience research.

[45]  R C Stevens,et al.  Crystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 A resolution. , 1998, Biochemistry.

[46]  J. Haavik,et al.  Tyrosine hydroxylase and Parkinson's disease , 1998, Molecular Neurobiology.

[47]  T. Flatmark,et al.  Generation of Reactive Oxygen Species by Tyrosine Hydroxylase: A Possible Contribution to the Degeneration of Dopaminergic Neurons? , 1997, Journal of neurochemistry.

[48]  T. Flatmark,et al.  Conformational Properties and Stability of Tyrosine Hydroxylase Studied by Infrared Spectroscopy , 1996, Journal of Biological Chemistry.

[49]  R. Surtees,et al.  Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. , 1996, Human molecular genetics.

[50]  T. Flatmark,et al.  Expression of recombinant human phenylalanine hydroxylase as fusion protein in Escherichia coli circumvents proteolytic degradation by host cell proteases. Isolation and characterization of the wild-type enzyme. , 1995, The Biochemical journal.

[51]  H. Fujisawa,et al.  Conversion of Tyrosine Hydroxylase to Stable and Inactive Form by the End Products , 1991, Journal of neurochemistry.

[52]  J. Mallet,et al.  Recombinant human tyrosine hydroxylase isozymes. Reconstitution with iron and inhibitory effect of other metal ions. , 1991, European journal of biochemistry.

[53]  T. Flatmark,et al.  Evidence from EPR spectroscopy that phosphorylation of Ser‐40 in bovine adrenal tyrosine hydroxylase facilitates the reduction of high‐spin Fe(III) under turnover conditions , 1989 .

[54]  H. Arai,et al.  Tyrosine Hydroxylase, Tryptophan Hydroxylase, Biopterin, and Neopterin in the Brains of Normal Controls and Patients with Senile Dementia of Alzheimer Type , 1987, Journal of neurochemistry.

[55]  J. Reinhard,et al.  A rapid and sensitive assay for tyrosine-3-monooxygenase based upon the release of 3H2O and adsorption of [3H]-tyrosine by charcoal. , 1986, Life sciences.

[56]  T. Flatmark,et al.  Rapid and sensitive assay of tyrosine 3-monooxygenase activity by high-performance liquid chromatography using the native fluorescence of DOPA. , 1980, Journal of chromatography.

[57]  Xavier Barril,et al.  Pharmacological chaperones for enzyme enhancement therapy in genetic diseases. , 2013, Pharmaceutical patent analyst.

[58]  Jian‐Qiang Fan,et al.  A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity , 2008, Biological chemistry.

[59]  M. Sawada,et al.  Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. , 2007, Journal of neural transmission. Supplementum.

[60]  P. Fitzpatrick,et al.  Tetrahydropterin-dependent amino acid hydroxylases. , 1999, Annual review of biochemistry.

[61]  T. Flatmark,et al.  Soluble tyrosine hydroxylase (tyrosine 3-monooxygenase) from bovine adrenal medulla: large-scale purification and physicochemical properties. , 1988, Biochimica et biophysica acta.